Where Does Pieris Pharmaceuticals Inc. (PIRS) Rank When It Comes To Price-To-Earnings Ratio?


Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) finished Wednesday with an addition of $0.07 to close at $0.95, an upside of 7.98 percent. An average of 522,920 shares of common stock have been traded in the last five days. There was a gain of $0.0002 in the past week, and it reached a new high 4 times over the past 12 months. The last 20 days have seen an average of 287,010 shares traded, while the 50-day average volume stands at 311,516.

PIRS stock has decreased by -5.92% in the last month. The company shares reached their 1-month lowest point of $0.8464 on 12/22/22. With the stock rallying to its 52-week high on 01/04/22, shares of the company touched a low of $0.85 and a high of $4.08 in 52 weeks. It has reached a new high 2 times so far this year and lost -74.86% or -$2.8298 in price. In spite of this, the price is down -76.69% from the 52-week high.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Valuation Metrics

Pieris Pharmaceuticals Inc. (PIRS) stock’s beta is 1.02. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2.40, the price-to-book (PB) ratio at 1.98.

Financial Health

The quick ratio of Pieris Pharmaceuticals Inc. for the three months ended June 29 was 2.30, and the current ratio was 2.30, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $83.25 million compared to revenue of $31.42 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Pieris Pharmaceuticals Inc.’s return on assets was -27.50%.

Earnings Surprise

For the three-month period that ended June 29, Pieris Pharmaceuticals Inc. had $21.4 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$9.74 million in the quarter, while revenues were shrunk -59.14%. The analyst consensus anticipated Pieris Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.11 per share, but it turned out to be -$0.14, a -27.30% surprise. For the quarter, EBITDA amounted to -$11.4 million. Shareholders own equity worth $74.41 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Pieris Pharmaceuticals Inc. (PIRS) price momentum. RSI 9-day as of the close on 28 December was 50.65%, suggesting the stock is Neutral, with historical volatility in this time frame at 60.00%.

As of today, PIRS’s price is $0.9062 +0.02% or $0.0002 from its 5-day moving average. PIRS is currently trading -4.53% lower than its 20-day SMA and -46.92% lower than its 100-day SMA. However, the stock’s current price level is -5.92% below the SMA50 and -67.23% below the SMA200.

The stochastic %K and %D were 34.61% and 29.99%, respectively, and the average true range (ATR) was 0.0743. With the 14-day stochastic at 53.62% and the average true range at 0.0714, the RSI (14) stands at 48.02%. The stock has reached -0.0240 on the 9-day MACD Oscillator while the 14-day reading was at -0.0342.

Analyst Ratings

Robert W. Baird upgraded Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) to a an Outperform rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Pieris Pharmaceuticals Inc. (PIRS) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell PIRS, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.

What is PIRS’s price target for the next 12 months?

Analysts predict a range of price targets between $7.00 and $7.00, with a median target of $7.00. Taking a look at these predictions, the average price target given by analysts for Pieris Pharmaceuticals Inc. (PIRS) stock is $7.00.


Please enter your comment!
Please enter your name here